Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**AAV2-shmTOR** is an investigational gene therapy designed to target and silence the mammalian target of rapamycin (mTOR) pathway in retinal cells. It utilizes an adeno-associated virus serotype 2 (AAV2) vector to deliver a short hairpin RNA (shRNA) specifically targeting mTOR mRNA, leading to its knockdown via RNA interference. The primary therapeutic goal is neuroprotection and preservation of vision in degenerative retinal diseases, such as geographic atrophy secondary to age-related macular degeneration (AMD). By inhibiting mTOR signaling, the therapy aims to reduce cell death and slow disease progression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AAV2-shmTOR.